All public logs

Jump to navigation Jump to search

Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).

Logs
(newest | oldest) View (newer 20 | ) (20 | 50 | 100 | 250 | 500)
  • 19:33, 17 April 2024 Hafiza Amna Qadeer talk contribs created page SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY (Created blank page)
  • 08:08, 17 April 2024 Edzelco talk contribs created page Elranatamab-bcmm (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:08, 17 April 2024 Edzelco talk contribs created page Palovarotene (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:08, 17 April 2024 Edzelco talk contribs created page Pozelimab-bbfg (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:07, 17 April 2024 Edzelco talk contribs created page Motixafortide (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:07, 17 April 2024 Edzelco talk contribs created page Momelotinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:06, 17 April 2024 Edzelco talk contribs created page Cipaglucosidase alfa-atga (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:05, 17 April 2024 Edzelco talk contribs created page Etrasimod (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:05, 17 April 2024 Edzelco talk contribs created page Zilucoplan (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:04, 17 April 2024 Edzelco talk contribs created page Bimekizumab (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:04, 17 April 2024 Edzelco talk contribs created page Vamorolone (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:04, 17 April 2024 Edzelco talk contribs created page Mirikizumab-mrkz (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:03, 17 April 2024 Edzelco talk contribs created page Toripalimab-tpzi (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
  • 08:02, 17 April 2024 Edzelco talk contribs created page Fruquintinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...")
  • 07:52, 17 April 2024 Edzelco talk contribs created page Taurolidine, heparin (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...")
  • 07:43, 17 April 2024 Edzelco talk contribs created page Repotrectinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru...")
  • 07:32, 17 April 2024 Edzelco talk contribs created page Efbemalenograstim alfa-vuxw (Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle....")
  • 05:50, 16 April 2024 Edzelco talk contribs created page Capivasertib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based...")
  • 05:27, 16 April 2024 Edzelco talk contribs created page Iptacopan (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me...")
  • 07:24, 15 April 2024 Edzelco talk contribs created page Vutrisiran (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj...")
(newest | oldest) View (newer 20 | ) (20 | 50 | 100 | 250 | 500)